Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: Potential implications in asthma and other lung diseases by Guéders, Maud et al.
Published in: European Journal of Pharmacology (2006), vol. 533, iss.1-3, pp. 133-144 
Status: Postprint (Author’s version) 
Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the 
respiratory tract: Potential implications in asthma and other lung diseases 
 
Maud M. Gueders, Jean-Michel Foidart, Agnès Noel, Didier D. Cataldo 
Department of Pneumology and department of Biology of Tumours and Development, Center for Biomedical Integrative Genoproteomics 
(CBIG), Belgium University of Liege and Centre Hospitalier Universitaire de Liège (CHU-Liège), Belgium 
 
Abstract 
In healthy lung, Matrix Metalloproteinases (MMPs) and their physiological inhibitors, tissue inhibitors of matrix 
metalloproteinases (TIMPs), are produced in the respiratory tract by a panel of different structural cells. These 
activities are mandatory for many physiological processes including development, wound healing and cell 
trafficking. Deregulation of proteolytic-antiproteolytic network and inappropriate secretion of various MMPs by 
stimulated structural or inflammatory cells is thought to take part to pathophysiology of numerous lung diseases 
including asthma, chronic obstructive pulmonary disease (COPD), lung fibrosis and lung cancer. Cytokines and 
growth factors are involved in these inflammatory processes and some of those mediators interact directly with 
MMPs and TIMPs leading either to a regulation of their expression or changes in their biological activities by 
proteolytic cleavage. In turn, cytokines and growth factors modulate secretion of MMPs establishing a complex 
network of reciprocal interactions. Every MMP seem to play a rather specific role and some variations of their 
expression are observed in different lung diseases. The precise role of these enzymes and their inhibitors is now 
studied in depth as they could represent relevant therapeutic targets for many diseases. Indeed, MMP inhibition 
can lead either to a decrease of the intensity of a pathological process or, in the contrary for some of them, to an 
increase of disease severity. In this review, we focus on the role played by MMPs and TIMPs in asthma and we 
provide an overview of their potential roles in COPD, lung fibrosis and lung cancer, with a special emphasis on 
loops including MMPs and cytokines and growth factors relevant in these diseases.  
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1. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) 
Matrix metalloproteinases (MMPs), or matrixins, belong to the metzincin superfamily of metalloproteinases, also 
including astacins, ADAMs (a protein with a disintegrin and metallopro-tease domain) and ADAM-TS proteases 
(ADAM with a thrombospondin-like motif) (Sternlicht and Werb, 2001; Folgueras et al., 2004; Handsley and 
Edwards, 2005; Noel et al., 2004). MMPs are proteolytic enzymes believed to be implicated in many 
physiological and pathological processes including embryonic development, morphogenesis, reproductive 
processes, bone remodeling, wound healing, cancer, arthritis, atherosclerosis, MMPs are zinc and calcium-
dependent enzymes being able to degrade virtually all extracellular matrix components. This can modulate cell 
behaviour by creating influential cellular environment (Shapiro, 1998). The extracellular matrix is a complex 
network of molecules including collagens, fibronectin, laminin, entactin/ nidogen and heparan sulfate 
proteoglycans (Mott and Werb, 2004). The extracellular matrix is a mechanical support for cells but also acts as 
a reservoir for cytokines and growth factors (vascular endothelial growth factor (VEGF), transforming growth 
factor-β (TGF-β),...). MMPs, by their proteolytic activity, can, on one hand, affect the adherence of cells to the 
extracellular matrix and, on the other hand, release both bioactive fragments of extracellular matrix molecules 
and "trapped" bioactive mediators, providing signals from the mic-roenvironment to cells allowing them to react 
to stimuli (Mott and Werb, 2004). For example, Laminin-5A, a component of basement membrane, is released 
from matrix by proteolytic activity of some MMPs (especially by MT1-MMP and MMP-2 activity) (Gilles et al., 
2001). It was shown that γ-2 chain of laminin-5 induces epithelial cell migration allowing MMP activity to 
participate in the regulation of epithelial cell behaviour. In this context, MMPs also play important positive or 
negative roles in angiogenesis by different mechanisms. MMP-9 has been for instance reported to be essential 
for the mobilization of VEGF from the extracellular matrix (Handsley and Edwards, 2005). MMP-2 and MMP-9 
promote angiogenesis by exposure of a cryptic epitope within collagen IV. In contrast, MMP-7 has the ability to 
generate anti-angiogenic factors by the release of endostatin fragments from the extracellular matrix. 
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Since their first description by Gross and Lapière (1962), 28 MMPs have been described and 24 MMPs have 
been identified in vertebrates (Table 1). MMPs taxonomy was first built according to their substrate specificity 
but another classification of MMPs based on their structural similarities was proposed by Egeblad and Werb 
(2002). MMPs are indeed made of different domains and most are secreted from cells as latent pro-enzymes 
requiring the cleavage of an amino-terminal domain of approximately 10 kDa (propeptide domain) to be 
activated. The precise mechanisms implicated in vivo in such an activation is still unknown but 
plasminogen/plasmin system is probably involved (Nagase, 1997). There are many structural differences among 
members of MMP family, participating in many cases in the fine tuning of proteolytic properties (substrates, 
activities,...) and in the regulation of protease-matrix interactions (adhesion, substrate selectivity). All MMPs 
share a pro-domain which contain in some cases a furin cleavage site allowing intracellular activation (MMP-11, 
MMP-21, MMP-23, MMP-28, MT-MMPs). In gelatinase subfamily of MMPs (MMP-2 and MMP-9), the 
catalytic domain that includes the Zn2+ binding site also contains repeats of fibronectin motifs allowing the 
ability to bind gelatin, their major substrate. Other domains shared by most MMPs are a proline-rich hinge 
region, a haemopexin-like domain responsible for most of substrate specificity and binding to specific inhibitors 
and, at least, a carboxy-terminal domain (Murphy and Willenbrock, 1995; Murphy and Knauper, 1997). 
Membrane-type MMPs (MT-MMPs) represents a subclass of MMPs that are anchored to the plasma membrane 
by an additional specific transmembrane domain (Sounni and Noel, 2005; Zucker et al., 2003). 
MMP synthesis and functions are regulated by three major mechanisms including transcriptional activation, 
post-transcrip-tional processing (release of pro-domain, cell surface shedding), and control of activity by a 
family of endogenous inhibitors collectively known as tissue inhibitors of metalloproteinases (TIMPs). 
Cytokines and growth factors, which display a rather complex relationship with MMPs as described in another 
section of this review, can act directly on the modulation of MMP gene expression (Lopez-Otin and Overall, 
2002). As an example, tumor necrosis factor-α (TNF-α) or interleukin-1 β (IL-1β) are able to induce induction of 
MMPs gene in tumours while TGF-β is rather known to be a repressor of the expression of MMPs genes. As 
mentioned above, MMPs are secreted in a latent form and need to be activated by proteolysis. This conversion of 
pro-MMP into activated form can be performed in vitro by reactive oxygen radicals or physical conditions like 
pH or temperature (Nagase, 1997). In vivo, MMP activation involves other MMPs or serine proteases (Noel et 
al., 2004). For instance, activation of proMMP-2 is performed by membrane bound membrane type-1 MMP 
(MT1-MMP) (Lewalle et al., 1995; Zucker et al., 2003). Another level of control for MMP activity is their 
inhibition by endogenous inhibitors like TIMPs and α2-macroglobulin. This latter is mainly present in the fluid 
phase of plasma while TIMPs are considered to be key inhibitors in tissues. To date, four TIMPs (TIMP-1 to 
TIMP-4) have been identified in vertebrates. TIMPs are composed of a N-terminal and a C-terminal domain 
stabilized by disulfide bounds. As for MMPs, TIMP expression in tissues is tightly regulated to maintain an 
equilibrium between proteolysis and proteolysis inhibition leading extracellular matrix as a stable medium 
maintaining plastic capacities. Deregulation of TIMPs or MMPs activities leads to states of either exaggerated 
extracellular matrix turnover often leading to remodelling via impaired repair and scar formation or extracellular 
matrix accumulation leading to fibrosis. The four TIMPs have different affinity for the different MMPs (Brew et 
al., 2000). TIMP-1, TIMP-2, TIMP-4 are secreted proteins whereas TIMP-3 is anchored in extracellular matrix 
(Baker et al., 2002). TIMPs inhibit MMPs in a 1:1 stoechiometric and reversible manner. 
TIMP-1 and TIMP-2 are able to make complexes with active forms of MMP-2 or MMP-9, and with the latent 
form of MMP-9 and MMP-2, respectively. TIMP-2 promotes an effective activation of proMMP-2 by formation 
of a ternary complex with MT1-MMP at cell surface. On the contrary, an excess of TIMP-2 inhibited proMMP-2 
activation (Strongin et al., 1995; Seiki et al., 2003). 
Many cell types have been identified as producers of MMPs and TIMPs in the lung. These enzymes and their 
inhibitors are produced by structural cells of the bronchial tree and alveolae and by inflammatory cells upon 
stimulation. In healthy lung, fibroblasts produce constitutively MMP-2, but are also a cellular source for MMP-1 
and TIMP-1. Bronchial epithelial cells release MMP-2, MMP-9 and their major inhibitor, TIMP-1. In addition to 
these latter, alveolar epithelial cells and particularly type II pneumocytes, produce TIMP-2 and MMP-1 (Xu et 
al., 2002). Smooth muscle cells produce MMP-2 which controls their proliferation (Johnson and Knox, 1999). 
Smooth muscle cells are also a source of MT1 -MMP, TIMP-1 and TIMP-2 and produce MMP-3 and MMP-7 
mRNA in moderate levels (Elshaw et al., 2004). Among inflammatory cells, neutrophils produce MMP-9, MMP-
8 and TIMP-1 which are synthesized and released from their secondary granules upon activation (Cataldo et al., 
2001). Alveolar macrophages produce MMP-1, MMP-9, MMP-12 and TIMP-1. Mast cells play a key role in 
inflammatory processes occurring in the bronchial wall and, once activated by lymphocytes, produce at least 
MMP-9 (Baram et al., 2001). 
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In pathological conditions, the activity and secretion profile of these cells can be modified, switching the 
expression and activity of MMPs and TIMPs and rendering this enzyme and their inhibitors implicated in many 
lung diseases as described below (Ohbayashi, 2002). 
 
Table 1: the matrix metalloproteinase family 




MMP-1 (collagenase-1) 52/41 Collagen I, II, II, VII, VIII, X, aggrecan, gelatin, pro-
MMP-2, pro-MMP-9 
MMP-8 (collagenase-2) 85/64 Collagen I, II, III, VII, VIII, X, aggrecan, gelatin 
MMP-13 (collagenase-3) 65/55 Collagen I, II, III, aggrecan, gelatin 
MMP-18 (collagenase-4) 53/42  
Gelatinases 
MMP-2 (Gelatinase-A) 72/66 Collagen I, II, III, IV, V, VII, X, XI, XIV, gelatin, elastin, 
fibronectin, aggrecan 
MMP-9 (Gelatinase-B) 92/85 Collagen IV, V, VII, X, XIV, gelatin, pro-MMP-9, pro-
MMP-13, elastin, aggrecan 
Stromelysins 
MMP-3 (Stromelysin-1) 57/45, 28 Collagen II, III, IV, IX, X, XI, elastin, pro-MMP-1, pro-
MMP-7, pro-MMP-8, pro-MMP-9, pro-MMP-13 
MMP-10 (Stromelysin-2) 56/47, 24 Collagen III, IV, V, gelatin, fibronectin 
MMP-11 (Stromelysin-3) 58/28 Fibronectin, laminin, gelatin, aggrecan 
Membrane-type MMPs 
MMP-14 (MT1-MMP) 66/60 Pro-MMP-2, pro-MMP-13, collagen I, II, III, gelatin, 
aggrecan, fibronectin, laminin 
MMP-15 (MT2-MMP) 68/62 Pro-MMP-2, gelatin, fibronectin, laminin 
MMP-16 (MT3-MMP) 64/55 Pro-MMP-2 
MMP-17 (MT4-MMP) 57/53 Unknown 
MMP-24 (MT5-MMP) 63/45 Pro-MMP-2 
MMP-25 (MT6-MMP) Unknown Gelatin 
Others 
MMP-7 (matrilysin-2) 28/19 Collagen II, III, IV, IX, X, XI, elastin, pro-MMP-1, pro-
MMP-7, pro-MMP-8, pro-MMP-9, pro-MMP-13, gelatin, 
aggrecan, fibronectin, laminin 
MMP-26 (matrilysin) 28/unknown Collagen IV, gelatin, fibronectin 
MMP-12 (metalloelastase) 54/45, 22 Elastin 
MMP-19 57/45 Tenascin, gelatin, aggrecan 
MMP-20 (enamelysin) 54/22 Enamel, gelatin 
MMP-21 70/53 Unknown 
MMP-23 Unknown Unknown 
MMP-27 Unknown Unknown 
MMP-28 (epilysin) Unknown/58, 55 Unknown 
 
2. Implication of MMPs in the pathogenesis of asthma 
Bronchial asthma is a pulmonary disorder characterized by the development of bronchial hyperresponsiveness, 
chronic persistent infiltration of the airway wall by inflammatory cells, and airways structural changes referred to 
as "bronchial remodeling". This latter probably leads to an increased rate of lung function decrease during the 
life (Lange et al., 1998). The main structural changes described in bronchi of asthmatics are: (a) an epithelial 
thickening and a sub-epithelial fibrosis mainly linked to deposition of different collagen subtypes (types I and 
III) and fibronectin, (b) some changes of extracellular matrix composition (e.g., elastic fibres fragmentation, 
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tenascin deposition,...), (c) smooth muscle cell hyperplasia, (d) mucus-producing cells ("Goblet cells") 
hyperplasia, (e) increase in the surface of blood vessels in airway walls, and (f) perichondral fibrosis (Bousquet 
et al., 1992; Cataldo et al., 2003; Vignola et al., 1998a). 
MMP-9 was the first MMP to be studied in depth for its implication in pathology of asthma. Increased levels of 
MMP-9 were indeed detected in bronchoalveolar lavage fluid (Mautino et al., 1997), sputum induced by the 
inhalation of hypertonic saline (Cataldo et al., 2000; Vignola et al., 1998b) and in serum of asthmatic patients 
(Bosse et al., 1999). The increased MMP-9 activity observed in the airways of asthmatic patients seems related 
to an increased number of granulocytes and more precisely neutrophils in the airways rather than to an 
enhancement of MMP-9 secretion by those cells (Cataldo et al., 2001; Prause et al., 2004). Other authors have 
suggested that eosinophils, key cells in asthma-related airway inflammation, could also be a major source for 
MMP-9 in this disease (Ohno et al., 1997). A significant correlation was indeed found in immunohistochemistry 
and in situ hybridisation between MMP-9 expression and eosinophil counts in bronchial mucosa. MMP-9 is also 
expressed by bronchial epithelium and may be an important factor promoting eosinophilic infiltration into the 
airways from patients suffering from asthma (Han et al., 2003; Ohno et al., 1997). Although the interest of 
investigating a balance between MMP-9 and TIMP-1 would probably be restricted to the pericellular area, some 
authors have reported an imbalance observed between MMP-9 and TIMP-1 measured in bronchial secretions or 
bronchoalveolar lavage, with a significant increase of TIMP-1 production when compared to that of MMP-9, 
thought to favouring extracellular matrix deposition (Mautino et al., 1999; Vignola et al., 1998b). However, 
other authors studying such fluids (bronchoalveolar lavage or induced sputum) or bronchial wall did not report 
such an imbalance suggesting that bronchial inflammation would lead to a proteolytic burden followed by scar 
formation resulting in a disorganised extracellular matrix (Cataldo et al., 2002a; Hoshino et al., 1999; Kelly et 
al., 2000). Moreover, in asthmatics, TIMP-1 was reported to be secreted in a lesser extent by granulocytes 
suggesting that it could exist an imbalance between proteolytic and anti-proteolytic activities at the pericellular 
level in the airway wall (Cataldo et al., 2002a; Hoshino et al., 1999; Kelly et al., 2000). 
MMP-9 levels were increased after allergen challenge in the sputum from allergic asthmatics as compared to 
control subjects and correlated to the percentage of eosinophils while TIMP-1 levels did not vary significantly 
(Cataldo et al., 2002a; Kelly et al., 2000). This observation suggests that extracellular matrix can be aggressed 
after allergen contact and are linked to allergen-induced acute bronchial inflammation. A significant correlation 
was observed between MMP-9 levels and both the maximum percent fall in forced expiratory volume at the first 
second (FEV1) during the late response and the number of neutrophils in sputum (Boulay et al., 2004). 
Severity of asthma is also a factor influencing protease secretion in airways. MMP-9 levels in sputum from 
patients with severe asthma, particularly those with nonreversible airway obstruction, are even higher when 
compared to patients with mild asthma (Mattos et al., 2002). In this context of severe disease, MMP-9 serum 
levels were also increased when compared to milder asthmatics (Belleguic et al., 2002). Therefore, MMP-9 level 
measurements could be proposed as a useful tool to determine one of the aspects of disease severity. 
Regulation of MMP-9 secretion in airways appears complex since both inflammatory and structural cells are able 
to produce that protease. On epithelial cell surface, protease-sensitive receptors can be found such as proteinase-
activated receptor-2 (PAR-2) which is activated mainly by serine proteases, such as trypsin and mast cell 
tryptase, and induce the release of MMP-9 by airway epithelial cells suggesting that these receptors could be 
implicated in tissue remodelling occurring in asthma (Vliagoftis et al., 2000). Besides MMP-9 release, PAR-2-
mediated activation of airway epithelial cells also induces release of granulocyte macrophage colony stimulating 
factor (GM-CSF) and eotaxin, which promotes eosinophil survival and activation, as well as recruitment of these 
inflammatory cells to airways, respectively (Vliagoftis et al., 2000). In vivo, intranasal stimulation of mice with 
IL-17, known to promote neutrophil recruitment, induced the release of proMMP-9 and active MMP-9 in 
bronchoalveolar lavage fluid, associated with a pronounced local accumulation of neutrophils displaying a 
positive staining for MMP-9 (Prause et al., 2004). In mouse models of asthma, the absence of MMP-9 is 
responsible for a decrease of infiltration of airways and bronchoalveolar lavage by inflammatory cells. MMP-9 
knock-out (KO) mice failed to develop allergen-induced airway hyperresponsiveness (Cataldo et al., 2002b). 
MMP-9 gene deletion seems to be effective on allergen-induced inflammatory process by decreasing dendritic 
cell trafficking, which is one of the key events during initiation of allergic immune responses including asthma 
(Vermaelen et al., 2003). Interestingly, another study using also MMP-9 KO mice reported that MMP-9 is not 
essential for leukocyte migration and that MMP-9 deletion could promote both airway inflammation and 
hyperresponsiveness (McMillan et al., 2004). The difference between those two last studies can be ascribed to a 
significant difference in allergen exposure protocol, the latter study being performed with a 5 time higher antigen 
concentration. 
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Neutrophils play a significant role in asthma as soon as the disease becomes severe (ENFUMOSA study group, 
2003). Besides MMP-9 production, neutrophils also produce MMP-8 that is stored in their secondary granules 
and released upon stimulation. An increase of MMP-8 expression has been reported in bronchial biopsies and in 
bronchoalveolar lavage from asthmatic patients suggesting that this enzyme could play an important role in this 
disease (Cataldo et al., 2001; Prikk et al., 2002). To verify this hypothesis, we recently applied a mouse model of 
asthma to MMP-8 deficient mice (MMP-8 KO) and we found surprisingly that mice lacking MMP-8 displayed a 
severe granulocytic inflammation in airways after allergen exposure (Gueders et al., 2005). In this model, 
neutrophil apoptosis was lower in MMP-8 KO mice after allergen exposure indicating a probable role for MMP-
8 in regulation of processes leading to neutrophil clearance. 
In addition to their potential role in airway inflammation described here, MMPs are also thought to play a 
significant role in tissue remodeling process. Inflammatory cells such as T cells, eosinophils and mast cells but 
also some structural cells such as smooth muscle cells are believed to cause irreversible airway structural 
changes by both MMP secretion and production of pro-inflammatory cytokines or growth factors that can be 
either activated or inactivated by proteolytic cleavage resulting from the activity of MMPs. For instance, 
deposition of collagen I, III and fibronectin in the reticular layer of basement membrane is thought to be caused 
by cycles of matrix degradation and impaired repair and could be favoured by an overproduction of activated 
TGF-β. This process involves probably at least MMP-2 and MMP-9 which share the ability to disrupt normal 
basement membrane. MMP-1, secreted by hyperplastic smooth muscle cells may play a role in hyperplasia of 
these latter, probably by activating insulin-like growth factor (IGFs) axis (Rajah et al., 1999). IGF-1 is indeed 
produced by airway epithelial cells and is a potent growth factor for airway smooth muscle cells proliferation 
perhaps by its ability to up-regulate MMP-2, a well recognized smooth muscle cell mitogen, at several levels 
(Zhang et al., 2004). In normal conditions, in humans, MMP-2 is secreted by airway smooth muscle cells and is 
effective on cell proliferation in an autocrine manner. Increased airway smooth muscle mass is perhaps the most 
important component of the airway wall remodeling process in asthma (Hirst and Twort, 1992). Inhibition of 
MMP-2 significantly reduces smooth muscle cells proliferation (Johnson and Knox, 1999). 
The picture is rendered even more complex when considering the interplay of different protease-antiprotease 
systems including plasminogen/plasmin system. Two plasminogen activators (urokinase-type plasminogen 
activator and tissue plasminogen activator (uPA and tPA)) convert plasminogen into plasmin (Noel et al., 2004). 
The main physiological inhibitor of plasminogen activators (plasminogen activator inhibitor-1 (PAI)-l) is known 
to regulate the adhesion and migration of a variety of cells during the inflammatory response (Blasi, 1999; Noel 
et al., 2004) and is thought to interact with MMP system in the lung. Indeed, PAI-1 is mainly produced by mast 
cells and may promote extracellular matrix deposition, at least by inhibiting MMP-9 activity (Cho et al., 2004). 
This afford the demonstration of the role played by PAI-1 in extracellular matrix homeostasis since those mice 
displayed less collagen and fibrin deposition in airway wall and higher MMP-9 activity (Oh et al., 2002). 
2.1. Interactions between MMPs and cytokines — growth factors in asthma 
Complex interactions occur between MMPs, TIMPs, cytokines and growth factors. In asthma, inflammation is 
driven by a specific subclass of T lymphocytes referred to as Th2 lymphocytes that orchestrate and perpetuate 
inflammation and remodeling through secretion of specific cytokines, mainly interleukin-4 (IL-4), IL-5, IL-9, 
and IL-13 (Renauld, 2001), playing distinct roles. IL-4 is the major factor regulating IgE production by B cells, 
and is required for optimal Th2 differentiation. Regarding the key role of cytokines in allergen-induced 
inflammatory processes, anti-cytokines therapies have been investigated in asthma. These studies revealed that 
blocking IL-4 is not sufficient to inhibit asthma development in experimental animal models. In contrast, 
inhibition of IL-13, another Th2 cytokine whose signal transduction pathway overlaps with that of IL-4, 
completely blocks airway hyperreactivity, subepithelial fibrosis and progression of inflammation in mouse 
asthma models. These effects were associated with an inhibition of MMP-9, neutralisation of IL-13 resulting in a 
reduction in total proteins MMP-9 levels in the lung tissue of mice (Yang et al., 2005). 
Some Th2 cytokines contribute in a significant manner to pathology of asthma and other lung inflammatory 
diseases by interacting directly with MMPs or TIMPs resulting in an increase or decrease of their expression and 
activity. IL-4 decreased MMP-2 protein and mRNA levels in human bronchial fibroblasts in culture but did not 
alter TIMP-2 production leading to an increased TIMP-2/MMP-2 ratio. In addition, IL-4 positively regulates 
procollagen I transcription by direct promoter activation thereby supporting the profibrotic effect of this 
cytokine. Based on these observations, IL-4 might be considered as a potential link between inflammation and 
collagen deposition observed in asthmatic airways (Bergeron et al., 2003). It has been described that MMP 
inhibitors administered intratracheally in a mouse model of asthma can exert a direct effect on cytokines and are 
able to significantly abrogate the increased expression of cytokines, including IL-4 mRNA in lung tissues and 
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IL-4 levels in bronchoalveolar lavage fluids (Lee et al., 2004). 
IL-5 is another major Th2 cytokine exerting an effect on eosinophils production, maturation, activation and 
acting as a strong chemotactic agent for those cells (Chung and Barnes, 1999). This cytokine could therefore 
significantly contribute to tissue damages observed in chronic asthma. IL-5 levels are increased in the 
bronchoalveolar lavage fluid of patients with symptomatic asthma. T cells, eosinophils and mast cells express 
IL-5 mRNA and secrete this cytokine. Eosinophils are known to express mainly MMP-9 but the influence of IL-
5 on this production is not yet demonstrated. Indeed, culture of peripheral blood eosinophils, in presence of IL-5, 
did not induce MMP-9 production after 4 days (Fujisawa et al., 1999). However, anti-IL-5 therapy markedly 
reduced peripheral blood and airway eosinophils and remodelling (decreased expression of tenascin and 
procollagen III, and decrease of the thickness of reticular basement membrane), but does not appear to be really 
effective on symptoms of asthmatic patients (Flood-Page et al., 2003). As some of these benefits might be linked 
to a specific interaction of IL-5 inhibition with members of the MMP family, some further studies should 
elucidate this particular point. 
IL-13 is thought to interact directly with many MMPs and TIMPs. In the lung, IL-13 is considered as a central 
regulator of allergic asthma by its contribution to the regulation of eosinophilic   inflammation,   subepithelial   
fibrosis,   mucus hypersecretion and airway hyperresponsiveness. IL-13 is a pleiotropic cytokine that either 
directly or indirectly affects the function of multiple cell types, including T cells, eosinophils, mast cells, 
basophils, epithelial cells, smooth muscle cells, fibroblasts and macrophages in many pathological conditions 
like inflammatory diseases of the lung or cancer (Kuperman et al., 2002). Exaggerated production of IL-13 has 
been documented in a variety of diseases characterized by inflammation and remodeling including asthma. IL-13 
has a direct effect on immune cells and is sufficient and necessary for the induction and the maintenance of 
allergen-induced activation of dendritic cells (Grunig et al., 2005). In a murine model of tobacco-induced lung 
damage, it has been described that IL-13 overexpression induces MMP-2, MMP-9, MMP-12, MMP-13, MMP-
14 expression (Zheng et al., 2000). Blocking MMPs in this model led to a significant decrease of IL-13-induced 
emphysema. IL-13-related effects such as alveolar enlargement and respiratory failure are especially mediated by 
MMP-9 and MMP-12-dependent pathways. MMP-9 inhibits rather neutrophils accumulation while MMP-12 
plays an inhibitory role on the eosinophils and macrophages accumulation (Lanone et al., 2002). In this picture, 
MMP-9 and MMP-12 could then be considered as downstream mediators and regulators of IL-13-induced 
inflammatory response. It has been described that IL-13 alone has no effect on TIMP-1 expression (Zhou et al., 
2005). However, in the presence of TGF-β1, IL-13 synergistically augments TIMP-1 mRNA, at a transcriptional 
level, and protein expression in human airway fibroblasts. TGF-β is a pro-fibrotic cytokine involved in 
remodeling and particularly in the formation of subepithelial fibrosis and levels of TGF-β are correlated with the 
thickness of basement membrane (Sagara et al., 2002). TGF-β is secreted by macrophages, fibroblasts, epithelial 
cells, smooth muscle cells but also by inflammatory cells including eosinophils, neutrophils and mast cells 
(Chung and Barnes, 1999). In normal conditions, TGF-β1 is present in the lower respiratory tract and mainly in 
bronchial epithelium. TGF-β levels measured in bronchial biopsies from asthmatics were elevated as compared 
to control subjects (Vignola et al., 1997). Loops of reciprocal control exist between TGF-β and MMPs since 
MMP-9 activates latent TGF-β, these latter, once activated acts directly on MMP-9 expression and plays a 
pivotal role increasing its production and secretion in a mouse model of remodeling (Ohbayashi, 2002; 
Santibanez et al., 2002). 
Other cytokines also display more or less complex interactions with members of the MMP family. Monocyte 
chemoat-tractant protein-1 (MCP-1) contributes undoubtfully to extracellular matrix changes observed during 
airway remodeling by increasing the mRNA for MMP-1 and TIMP-1 expression in cells from the bronchial 
secretions in asthmatics (Cataldo et al., 2002a). IL-1β, a pro-inflammatory cytokine, is increased in lungs of 
patients with asthma and is converted from its latent form by different proteases including MMP-9 (Schonbeck 
et al., 1998). Production of biologically active IL-1β expression in lungs of adult mice causes pulmonary 
inflammation characterized by neutrophil and macrophage infiltration. IL-1β has also been reported to contribute 
to fibrosis in airway walls increasing the thickness of conducting airway walls, and to enhance mucus 
production. These effects of IL-1β could be explained by its ability to increase the production of the neutrophil 
attractant CXC chemokines "cytokine-induced neutrophil chemoattractant" referred to as "KC" (CXCL1) and 
macrophage inflammatory protein-2 (MIP-2) (CXCL2), and the levels of matrix metalloproteinases MMP-9 and 
MMP-12 (Lappalainen et al., 2005). 
Relationship between the production of MMP-2 and the insulin-like growth factors (IGF) was previously 
discussed. Other growth factors as fibroblast growth factor (FGF), which is found associated with extracellular 
matrix, can have direct effect on MMPs production by fibroblasts. Indeed FGF-1, in presence of heparin which 
strongly enhances its effect, induces a marked upregulation of MMP-1 secretion in fibroblasts that do not express 
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the enzyme at the basal level (Becerril et al., 1999). On the contrary, the constitutive production of TIMP-1 and 
TIMP-2 by human lung fibroblasts in vitro is not significantly modulated by stimulation by FGF alone or FGF in 
combination with heparin. Platelet derived growth factor (PDGF) is released from very different cells in airways 
including airway epithelial cells, fibroblasts, endothelial cells, macrophages and smooth muscle cells. The 
release of PDGF by fibroblasts and by endothelial cells can be induced by TNF-α, TGF-β, IL-1β, hypoxia and 
FGF. PDGF could be a key actor of bronchial remodelling in asthma in that it stimulates lung fibroblast 
proliferation. PDGF also stimulates fibroblasts chemotaxis and MMP-1 production by those cells. This 
stimulation is increased by combining PDGF with IL-1β and TNF-α. IL1-β and TNF-α display inhibitory effects 
on MMP-2 and MMP-9 production. PDGF, in combination with IL-1β and TNF-α, induced MMP-3 and MMP-9 
activity. These findings suggest that PDGF differentially regulated MMP production in combination with 
cytokines. 
2.2. New therapeutic insights in asthma 
Based on the observation of increased levels of MMPs in asthmatic patients and taking into account the potential 
risk of side effects of broad spectrum inhibitors of metalloproteinases that have led to the discontinuation of most 
clinical trials in the field of cancer (Folgueras et al., 2004), the need for studying specific roles played by 
individual MMPs appears obvious. This was performed in many cases using MMP deficient mice (MMP-2, -8, -
9 and -12). Results of gene deletion for MMP-8 and -9 were discussed above. The application of a model of 
allergic asthma on MMP-2-deficient mice, revealed that MMP-2 deletion causes inflammatory cell infiltration of 
alveolae and a decrease of inflammatory cells recovered in bronchoalveolar lavage despite a strong 
peribronchovascular cell accumulation (Cony et al., 2002). These observations suggest that MMP-2 plays a role 
in the luminal clearance of inflammatory cells. MMP-12 Knock-Out mice were also investigated and the main 
finding was a decrease in most of inflammatory cells after allergen exposure as compared to the wild-type mice 
(Warner et al., 2004). 
Inhaled corticosteroid treatment is the mainstay of asthma therapy as soon as the disease reaches the mild 
persistent severity step (GINA Guidelines, 1995). This class of drugs could have a curative effect on remodeling 
by reducing subepithelial collagen deposition, probably by downregulation of MMP-9 expression and 
upregulation of TIMP-1 expression (Hoshino et al., 1999). This observation was however not confirmed by other 
authors. In sputum cells studied ex vivo, steroids reduced both MMP-9 and TIMP-1 production (Profita et al., 
2004). MMPs could represent an interesting therapeutic target in asthma since some reports indicate the validity 
of a MMP inhibition-based approach for asthma therapy in animal models. Indeed, airway inflammation and 
hyperresponsiveness were shown to be reduced by administration of recombinant TIMP-2 in the bronchial tree 
(Kumagai et al., 1999). TIMP-2 appears to be effective in preventing extracellular matrix damages at least in part 
by inhibition of MMP-2 and related proteolytic activity (Kumagai et al., 2002). The effect of doxycycline (a 
broad-spectrum MMP inhibitor) and other synthetic non-specific inhibitors on bronchial inflammation and 
airway hyperresponsiveness was evaluated by the use of a murine model for TDI-induced asthma. After oral 
administration of doxycycline, mice display a decreased airway inflammation, airway hyperresponsiveness, and 
a decreased expression of MMP-9 at mRNA and protein levels (Lee et al., 2001, 2004). Other in vitro studies 
suggest that non-specific MMP inhibition by GM-6001 could lead to a decrease of goblet cell hyperplasia, one of 
the components of airway remodeling in asthma (Yoshisue and Hasegawa, 2004). 
Taken together, these data identify MMPs as potential therapeutic targets in asthma. One would expect that a 
nonspecific MMP inhibition would lead to some adverse events since the deletion of some of the MMP family 
aggravates the allergen-induced inflammation as a direct consequence. However, the first few trials in vitro and 
in vivo on animal models were performed with some inhibitors known for their nonspecific effect on MMP 
activity and seem to control adequately allergen-induced inflammation without obvious side effects. Should a 
specific MMP inhibitor be selected, it seems logical in view of the current literature to target MMP-9 in priority. 
It seems also logical to avoid a systemic inhibition of collage-nases, responsible for most of the osteo-articular 
side effects (Wojtowicz-Praga et al., 1998). 
3. Potential roles of MMPs in other pulmonary diseases 
3.1. Chronic obstructive pulmonary disease (COPD) 
The incidence of chronic obstructive pulmonary disease (COPD) is increasing worldwide and is ranked as the 
fourth most common cause of death in the United States. COPD is caused by long-term exposure to cigarette 
smoke, toxic gases, and particulate matter, leading to airflow limitation and pulmonary failure. The disease is 
characterized by an excess of extracellular matrix deposition in bronchial walls, chronic cough, sputum 
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production and destruction of alveolar septa, resulting in reduced functional lung parenchyma and reduced 
elastic tethering forces that maintain airways open. Like asthma, COPD is characterized by airway flow 
obstruction and a chronic persistent inflammatory process but these diseases are very different in terms of 
cellular mechanisms, nature of inflammation and response to therapy (Jeffery, 2001). Approximately 10% of 
COPD patients also have asthma and COPD is often managed in clinical practice as poorly responsive asthma 
(Barnes, 2000). The development of extensive tissue remodelling in COPD causes destruction of small bronchi 
and alveolae, leading to emphysema and involves many members of the MMP family. 
Matrix metalloproteinases have been suggested from recent studies as the major proteolytic enzymes involved in 
the pathogenesis of COPD. Increased levels of MMP-1 and MMP-9 have been detected in bronchoalveolar 
lavage fluid of patients with emphysema (Finlay et al., 1997b). As compared with healthy subjects, patients with 
COPD have a marked increase in expression and activity of MMP-2, MMP-9 and MT1-MMP in their lung 
parenchyma (Ohnishi et al., 1998) and increased gelatinolytic activity linked to MMP-2 and MMP-9 in their 
sputum (Cataldo et al., 2000; Vignola et al., 1998b). In bronchoalveolar lavage fluid of smokers with 
emphysema, an increase of collagenolytic activity, probably due to elevated levels of MMP-8, is measured when 
compared to smokers without emphysema (Betsuyaku et al., 1999) indicating that injury to the collagen network 
of the lung is also a part of the disease. When studied ex vivo, alveolar macrophages from patients with 
emphysema express more MMP-1 and MMP-9 than macrophages from healthy subjects suggesting that 
macrophages are the main cellular source of MMP-1 and MMP-9 in COPD (Finlay et al., 1997a). As it has a 
potent elastolytic activity, MMP-12 is thought to play a determinant role in development of COPD and 
emphysema. Experimental data show that mice exposed to cigarette smoke express more MMP-12 mRNA than 
non-exposed mice (Bracke et al., 2005). MMP-12 gene deletion in mice protects from the development of 
emphysema after long term exposure to cigarette smoke (Hautamaki et al., 1997). Alveolar macrophages were 
considered to be the unique source of MMP-12 (macrophage metalloelastase). Recently, it was demonstrated that 
MMP-12 is also expressed and secreted by normal human bronchial epithelial cell cultures (Lavigne et al., 
2004). These findings indicate that bronchial epithelium may be an important source of elastolytic activity in 
COPD. Taken together, these elements suggest that MMP-12 could be seriously considered as a potential target 
for COPD treatment (Nenan et al., 2005). Indeed, some reports establish the potential interest for a MMP 
inhibition-based approach in COPD, based on results obtained in animal models. Orally bioavailable synthetic 
MMP inhibitors were showed to decrease the rapidity of alveolar destruction in murine and Guinea Pig models 
of tobacco smoke exposure (Martin et al., 2001). 
3.2. Lung fibrosis 
Pulmonary fibrosis is a severe chronic disease characterized by a loss of lung epithelial cells, replaced by 
interstitial myofibroblasts and deposition of extracellular matrix proteins in the lung  interstitium  leading  to  
pulmonary  structural remodeling (Crouch, 1990). Idiopathic pulmonary fibrosis (IPF) is a chronic, usually fatal, 
disorder characterized by excessive matrix degradation and interstitial and intraalveolar fibrosis leading to 
dyspnea, impaired oxygen transfer and alveolar collapse (Katzenstein and Myers, 1998). The defects in the 
alveolar epithelium and basement membrane allow the migration of mesenchymal cells from the interstitium into 
the intraluminal compartment. Intraluminal fibrosis is one of the major characteristics of IPF and is associated 
with recruitment of inflammatory cells, particularly, macrophages, neutrophils and lymphocytes in the airways 
leading to an imbalance between the synthesis and degradation of extracellular matrix molecules in the local lung 
environment (Morimoto et al., 2005; Selman et al., 2000). 
In lung fibrosis, a temporal difference is observed in expression and localisation of MMPs and TIMPs 
(Swiderski et al., 1998; Yaguchi et al., 1998). In the early stage of this disease, gelatinolytic activity of MMP-9 
seems predominant and probably contributes to disruption of alveolar epithelial basement membrane, and 
enhances fibroblast invasion to alveolar spaces. MMP-9 and MMP-1 are released by infiltrating neutrophils, 
macrophages, bronchial and bronchiolar epithelial cells. In vivo, it was shown that gelatinase B (MMP-9) 
expression is increased in cultured alveolar macrophages and in bronchoalveolar lavage fluid from patients 
suffering from idiopathic pulmonary fibrosis. In vitro, MMP-9 expression in cultured alveolar macrophages is 
decreased by a treatment with steroids and immunosuppressive agents. In the late stages of the disease, MMP-2 
(in latent and active forms) seems to become predominant. MMP-2 is localized in structural cells like 
regenerated alveolar epithelial, bronchial epithelial cells and fibroblasts. In lung fibrosis, MMP-2 could play a 
role in the regeneration of alveolar epithelial cells (Fukuda et al., 1998; Lemjabbar et al., 1999; Manoury et al., 
2005; Scabilloni et al., 2005). The expression of the two gelatinases (MMP-2 and MMP-9) at different stages of 
fibrosis suggests that MMP-9 could be rather linked to inflammation-induced tissue remodeling, while MMP-2 
may be associated with an impaired tissue remodeling leading to pathological collagen deposition and interstitial 
fibrosis. 
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Besides the implication of gelatinases, MMP-7 is identified as a potential target for therapy of patients with IPF 
as MMP-7 gene is detected to be overexpressed by micro-array gene analysis (Cosgrove et al., 2002). Indeed, 
MMP-7 deficiency (MMP-7 KO mice) is shown to hamper the experimental pulmonary fibrosis in a mouse 
model (Zuo et al., 2002). As far as collagen accumulation is a mainstay of lung fibrosis, the downregulation of 
collagenases, which share the ability to cleave the native helix of fibrillar collagens, could also play a significant 
role in disease progression. Indeed, a decreased expression of MMP-8 and MMP-13 have been described in a rat 
model of lung fibrosis (Ruiz et al., 2003). In line with this observation, there is an overexpression of TIMPs 
leading to an imbalance between MMPs and their inhibitors resulting in a micro environment unfavourable to 
collagenolytic activity (Selman et al., 2000). TIMP-1, TIMP-2 and TIMP-3 are produced by different cells and 
have distinct roles in MMPs activity regulation. TIMP-2 is mainly localized in regenerated epithelial cells and in 
fibroblasts (Fukuda et al., 1998). TIMP-1 was primarily expressed on alveolar macrophages and epithelial cells. 
TIMP-2 and TIMP-3 genes were constitutively expressed whereas TIMP-1 gene expression is up-regulated 
during fibrosis. TIMP-1 expression is correlated with stages of disease progression and may prevent MMP-
induced extracellular matrix degradation, and, as a consequence, may participate in the accumulation of 
extracellular matrix. MMP detection could be proposed as a prognosis factor in lung fibrosis as described for 
MMP-9 (Lemjabbar et al., 1999). 
In the perspective of re-establishing the protease/antipro-teases homeostasis, some different approaches could be 
considered. First, antiprotease therapy has been proposed in lung fibrosis in the hope to control the disease 
extension and to have a preventive effect. Corbel et al. showed that bleomycin-induced pulmonary fibrosis was 
prevented by the administration of the MMP-inhibitor batimastat (Corbel et al., 2002). Alternatively, it could be 
considered that an hypothetical therapeutic intervention that would allow the MMP activity to control the 
collagen accumulation by tight regulation of TIMP activity should be experimented as a curative approach of the 
disease. 
3.3. Role of MMPs in lung cancer 
By their ability to disrupt the extracellular matrix allowing cell migration and release of bioactive molecules, 
MMPs contribute to the formation of a complex micro environment that promotes malignant transformation and 
cancer progression (Folgueras et al., 2004; Handsley and Edwards, 2005; Sounni and Noel, 2005). MMPs take 
part to the processes leading to metastasis to distant sites. Many experimental data are now available about the 
expression of different MMPs in cancer and we can cite here only a few of them. 
MMP-9 and TIMP-1 are elevated in the serum of patients with both Small Cell Lung Cancer (SCLC) and Non-
Small Cell Lung Cancer (NSCLC), when compared to healthy subjects modifying the natural physiological 
relationship between MMP-9 and TIMP-1 (Jumper et al., 2004). 
In NSCLC, MMP-1 and gelatinases (MMP-2 and MMP-9) contribute to tumor invasion and metastasis and have 
been proposed as reliable prognostic factors (Reichenberger et al., 2001). Overexpression of MMP-1 is 
associated with a particularly poor prognosis in lung carcinoma as described for other cancer types (Kodate et 
al., 1997). The destruction of basement membrane (type IV collagen) or MMP-2 expression correlated with the 
prognosis of invasive lung adenocarcinomas (Pritchard et al., 2001). Elevated levels of MT1-MMP are also 
linked to a poor prognosis (Tokuraku et al., 1995). MMP expression could also vary in function of cancer 
subtypes. MMP-11, MMP-13, MMP-14, TIMP-2 and TIMP-3 are indeed more frequently expressed than MMP-
1 and MMP-9 and the role played by some of these enzymes appears to be different in SCLC and NSCLC 
(Michael et al., 1999). Strong MMP-2 expression in stromal fibroblasts was more frequently seen in squamous 
cell carcinoma than in adenocarcinoma, two different types of NSCLC. MMP-2 could play a role in tumour-
related angiogenesis since tumours with strong MMP-2 expression in stromal fibroblasts showed a significantly 
higher intratumoral microvessel density. Moreover, combined overexpression of VEGF and MMP-2 is 
associated with a poor prognosis (Shou et al., 2001). In addition, postoperative prognosis was linked to stromal 
MMP-2. MMP-2 expression by tumour stroma fibroblasts could thus be considered as a good prognostic factor 
associated with angiogenesis and survival in NSCLC (Ishikawa et al., 2004). Elevated levels of plasma MMP-9 
were observed in patients with NSCLC but the role of MMP-9 as a marker of lung cancer is still unclear. In 
NSCLC, MMP-9 seems to play a role in the process leading to metastasis development. Metastatic dissemination 
was hampered in MMP-9-deficient mice when compared to wild-type control mice in a mouse model of cancer 
dissemination (Itoh et al., 1999). The expression of TIMPs (particularly TIMP-1 and TIMP-2) was correlated 
with the cancer stage (Thomas et al., 2000) and their levels have been proposed to be used as prognosis markers 
of lung adenocarcinoma progression (Ylisirnio et al., 2000). 
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3.4. Antiprotease therapy in cancer 
The first generation of MMP inhibitors, used in cancer therapy, were not successful and most of clinical trials 
were aborted in early stages. This is probably due to the complex role of MMPs and TIMPs, being involved in 
multiple loops of reciprocal interaction in physiological and pathological conditions (Folgueras et al., 2004) and 
to the toxicity of systemic MMP inhibition. Different broad spectrum MMP inhibitors like Batimastat (BB94) or 
Prinomastat failed at phase I and III of clinical trials, respectively and development of several other MMP 
inhibitors was stopped due to their systemic toxicity and poor efficacy (Hoekstra et al., 2001). As synthetic 
MMP inhibitors are rather toxic, one could address the use of TIMPs. TIMPs used as MMP inhibitors in 
different diseases have revealed some paradoxical effects. For example, TIMP-4 up-regulates anti-apoptotic 
protein Bcl-X, thereby stimulating mammary tumourigenesis (Jiang et al., 2001). TIMPs (and synthetic 
inhibitors) may also block the activity of MMPs that are not necessarily overexpressed in tumour or play 
protective roles against cancer such as MMP-8 for instance (Balbin et al., 2003). These observations highlight 
the need for developing new strategies of MMP inhibition. Different strategies could be investigated. First, 
generation of new synthetic MMP inhibitors that inhibit individual MMPs would allow a control of specific 
processes related to tumour progression. However, this approach is still hypothetical since MMPs share many 
structural features with an active site very conserved among members of this proteases class. Another approach 
would be a targeting one, allowing MMP inhibitor delivery at the tumour site thereby allowing the use of high 
local therapeutic concentrations and a decrease of systemic toxicity. For lung cancer, aerosol administration 
could also be considered since it would increase the therapeutic index and allow higher concentration in the 
target organ. To the best of our knowledge, no clinical trials have been conducted to date using such a strategy. 
4. Conclusion 
In conclusion, MMPs and their inhibitors (TIMPs) play multiple functions in physiological processes and 
interact with many other mediators regulating inflammatory processes, cell behaviour, and angiogenesis,... These 
mediators are implicated in many intricate loops of reciprocal interactions rendering the understanding of the 
role of MMPs in regulatory processes difficult. In many diseases, MMPs are overexpressed or oversecreted 
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